Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts

Publisher Name :
Date: 01-Oct-2016
No. of pages: 191

"Delivery of this report will take 1-3 days after purchase."

The Global Cancer Vaccine Partnering 2010-2016 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in cancer vaccine partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Cancer vaccine partnering contract documents

Top cancer vaccine deals by value

The Global Cancer Vaccine Partnering 2010-2016 report provides an understanding and access to the cancer vaccine partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer vaccine partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors vaccine technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report also includes adjuvant deals and alliances.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 150 links to online copies of actual cancer vaccine deals and where available, contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

This report provides details of the latest cancer vaccine agreements announced in the healthcare sectors covering the following diagnostics types including adjuvant.

Attenuated vaccine

Subunit vaccine

Toxoid vaccine

Conjugate vaccine

Inactivated vaccine

DNA vaccine

Recombinant vector vaccine

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive cancer vaccine deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering cancer vaccine partnering deals.

The report presents average financial deal terms values for cancer vaccine deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The middle section of the report explores the leaders in the cancer vaccine partnering field; both the leading deal values and leading players are reported allowing readers to see who is succeeding in this growing market. This chapter also looks at the contributions by the big pharma and big biotech companies of the world in terms of deals made.

One of the key highlights of the report is that over 150 online deals records of actual cancer vaccine deals as disclosed by the deal parties are included towards the end of the report in a directory format that is easy to reference. Each deal links via Weblink to an online version and all these deals are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy and technology focus. In addition the report includes actual contract documents where available as submitted to the Securities Exchange Commission by companies and their deal partners.

Report scope

Global Cancer Vaccine Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to cancer vaccine trends and structure of deals entered into by leading companies worldwide.

Global Cancer Vaccine Partnering 2010-2015 includes:

Trends in cancer vaccine dealmaking in the biopharma industry since 2010

Analysis of cancer vaccine deal structure

Access to headline, upfront, milestone and royalty data

Access to over 150 cancer vaccine deal records

The leading cancer vaccine deals by value since 2010

In Global Cancer Vaccine Partnering 2010-2015 , the available deals are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific oncology therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Global Cancer Vaccine Partnering 2010-2015 report provides comprehensive access to available deals and contract documents for over 160 cancer vaccine deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?

What is actually granted by the agreement to the partner company?

What exclusivity is granted?

What is the payment structure for the deal?

How aresales and payments audited?

What is the deal term?

How are the key terms of the agreement defined?

How are IPRs handled and owned?

Who is responsible for commercialization?

Who is responsible for development, supply, and manufacture?

How is confidentiality and publication managed?

How are disputes to be resolved?

Under what conditions can the deal be terminated?

What happens when there is a change of ownership?

What sublicensing and subcontracting provisions have been agreed?

Which boilerplate clauses does the company insist upon?

Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Global Cancer Vaccine Partnering 2010-2016 provides the reader with the following key benefits:

In-depth understanding of cancer vaccine deal trends since 2010

Access to headline, upfront, milestone and royalty data

Acces to the structure of cancer vaccine agreements with numerous real life case studies

Comprehensive access to over 150 actual cancer vaccine deals entered into by the world's biopharma companies, together with real world clause examples

Full listing of cancer vaccine deals by company A-Z, deal value, phase of development, deal type, and therapy focus

Identify leading cancer vaccine deals by value since 2010

Identify the most active cancer vaccine dealmakers since 2010

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Global Cancer Vaccine Partnering 2010-2016: Deal trends, players, financials and forecasts

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Cancer Vaccine dealmaking
2.1. Introduction
2.2. Cancer Vaccine partnering over the years
2.3. Most active Cancer Vaccine dealmakers
2.4. Cancer Vaccine partnering by deal type
2.5. Cancer Vaccine partnering by therapy area
2.6. Deal terms for Cancer Vaccine partnering
2.6.1 Cancer Vaccine partnering headline values
2.6.2 Cancer Vaccine deal upfront payments7
2.6.3 Cancer Vaccine deal milestone payments
2.6.4 Cancer Vaccine royalty rates

Chapter 3 - Leading Cancer Vaccine deals
3.1. Introduction
3.2. Top Cancer Vaccine deals by value

Chapter 4 - Most active Cancer Vaccine dealmakers
4.1. Introduction
4.2. Most active Cancer Vaccine dealmakers
4.3. Most active Cancer Vaccine partnering company profiles

Chapter 5 - Cancer Vaccine contracts dealmaking directory
5.1. Introduction
5.2. Cancer Vaccine contracts dealmaking directory

Chapter 6 - Cancer Vaccine dealmaking by technology type

Chapter 7 - Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking

Appendices
Appendix 1 - Cancer Vaccine deals by company A-Z
Appendix 2 - Cancer Vaccine deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 - Cancer Vaccine deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Litigation
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Warranty
Appendix 4 - Cancer Vaccine deals by therapy area
Appendix 5 -Deal type definitions
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering

List of Figures

Figure 1: Cancer Vaccine partnering since 2010
Figure 2: Active Cancer Vaccine dealmaking activity- 2010 to 2016
Figure 3: Cancer Vaccine partnering by deal type since 2010
Figure 4: Cancer Vaccine partnering by disease type since 2010
Figure 5: Cancer Vaccine deals with a headline value
Figure 6: Cancer Vaccine deals with an upfront value
Figure 7: Cancer Vaccine deals with a milestone value
Figure 8: Cancer Vaccine deals with a royalty rate value
Figure 9: Top Cancer Vaccine deals by value since 2010
Figure 10: Most active Cancer Vaccine dealmakers 2010 to 2016
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
  • Asia Pacific Makeup Market To Grow Owing To Impactful Promotion And Progress Of Distribution Networks
    The Asia Pacific makeup market is one of the most assorted and active markets in the cosmetics industry throughout the world and is projected to grow at a CAGR of 7.1% between 2013 and 2019. The makeup market in Asia Pacific is assessed to be worth US$22.31 billion by 2019. The world-wide market was at an approximation of US$14.76 [...]
  • Growing Demand in Emergent Markets To Boost Bakery Ingredients Market
    The baking ingredients market is predictable to grow at a CAGR of 5.2% from 2015 to reach an estimated value of US$ 15.19 billion by 2020. Evolving economies throughout the globe have been displaying demand for bakery ingredients at a greater rate in agreement with the economic growth. Numerous companies have been occupied on refining [...]
  • Packaging Sector Driven By Innovation
    The financial development in numerous emerging nations has significantly influenced the progress of quite a lot of sectors, the packaging industry being one of them. The swell in transport undertakings outfitting to a substantial number of industries such as manufacturing, consumer goods, food and beverages, and others rest essentially on sturdy and resilient packaging solutions [...]
  • Global Eyewear Market To Gain From Increased Demand For Disposable Contact Lenses
    The global eyewear market was worth US$ 102.66 billion in 2015 and is predictable to reach US$ 184.03 billion by 2024. The rising population and upsurge in the number of optical disorders are likely to propel the industry in the near future. Moreover, the increasing cognizance amongst people as regards to the prominence of eye [...]
  • Global mHealth Market To Become A Multi-Billion Dollar Industry By 2020
    The mHealth market is in its embryonic stage and is projected to produce substantial profits with amassed awareness level and encouraging regulatory guidelines particular to the quality and practicality of mobile-based medical devices. The global mHealth market is projected to touch US$ 49.12 billion by 2020 rising at a CAGR of 47.6% from 2013 to 2020. Monitoring services [...]
  • China Cervical Cancer Vaccine Market Research Report 2016
    Published: 12-Dec-2016        Price: US 3200 Onwards        Pages: 103
    Notes: Sales, means the sales volume of Cervical Cancer Vaccine Revenue, means the sales value of Cervical Cancer Vaccine This report studies Cervical Cancer Vaccine in China market, focuses on the top players in China market, with capacity, production, price, revenue and market share for each manufacturer, covering - MSD - GSK Split by product type, with production, revenue, price, market share and growth rate of each type, can be divide......
  • Europe Cervical Cancer Vaccine Market Report 2016
    Published: 05-Dec-2016        Price: US 3900 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Cervical Cancer Vaccine Revenue, means the sales value of Cervical Cancer Vaccine This report studies sales (consumption) of Cervical Cancer Vaccine in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - MSD - GSK Market Segment by Coun......
  • United States Cervical Cancer Vaccine Market Report 2016
    Published: 29-Nov-2016        Price: US 3800 Onwards        Pages: 96
    Notes: Sales, means the sales volume of Cervical Cancer Vaccine Revenue, means the sales value of Cervical Cancer Vaccine This report studies sales (consumption) of Cervical Cancer Vaccine in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - MSD - GSK Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into......
  • Global Cervical Cancer Vaccine Sales Market Report 2016
    Published: 22-Nov-2016        Price: US 4000 Onwards        Pages: 102
    Notes: Sales, means the sales volume of Cervical Cancer Vaccine Revenue, means the sales value of Cervical Cancer Vaccine This report studies sales (consumption) of Cervical Cancer Vaccine in Global market, especially in United States, China, Europe, Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - MSD - GSK - ... Market Segment by Regions, th......
  • Global Cervical Cancer Vaccine Market Research Report 2016
    Published: 14-Nov-2016        Price: US 2900 Onwards        Pages: 101
    Notes: Production, means the output of Cervical Cancer Vaccine Revenue, means the sales value of Cervical Cancer Vaccine This report studies Cervical Cancer Vaccine in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with Production, price, revenue and market share for each manufacturer, covering - MSD - GSK - ... Market Segment by Regions, this repor......
  • Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19
    Published: 01-Nov-2016        Price: US 4995 Onwards        Pages: 183
    Cancer vaccines are being developed as a method of preventing certain types of cancer, and as therapeutic treatments to treat existing cancers across a range of indications in oncology, either as stand-alone therapies or in combination with traditional cancer therapeutics such as chemotherapy and surgery. The high mortality rate associated with cancer and its resistance to conventional treatments such as radiation and chemotherapy has led to the investigation of a variety of anti-cancer immun......
  • Europe BCG Vaccine Market Report 2016
    Published: 31-Oct-2016        Price: US 3900 Onwards        Pages: 128
    Notes: Sales, means the sales volume of BCG Vaccine Revenue, means the sales value of BCG Vaccine This report studies sales (consumption) of BCG Vaccine in Europe market, especially in Germany, UK, France, Russia, Italy, Benelux and Spain, focuses on top players in these countries, with sales, price, revenue and market share for each player in these Countries, covering - Merck - Sanofi Pasteur - Intervax - Japan BCG Laboratory - Ser......
  • United States BCG Vaccine Market Report 2016
    Published: 24-Oct-2016        Price: US 3800 Onwards        Pages: 123
    Notes: Sales, means the sales volume of BCG Vaccine Revenue, means the sales value of BCG Vaccine This report studies sales (consumption) of BCG Vaccine in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering - Merck - Sanofi Pasteur - Intervax - Japan BCG Laboratory - Serum Institute of India - Statens Serum Institute - GSBPL - CDIBP - SI......
  • Europe Lung Cancer Vaccines Sales Market Report 2021
    Published: 04-Aug-2016        Price: US 4900 Onwards        Pages: 108
    This report studies sales (consumption) of Lung Cancer Vaccines in Europe market, especially in Germany, UK, France, Italy, Spain and Russia, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering - Boehringer Ingelheim - CureVac - Eli Lily - GlaxoSmithKline - ImClone Systems - Merck - Ono Pharmaceutical - Oncothyreon Incorporation Market Segme......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs